The Influence of Fetal Hemoglobin on the Clinical Expression of Sickle Cell Anemia

• Published in: Annals of the New York Academy of Sciences 1989-01, Vol.565 (1), p.262-278
• Main Authors: POWARS, D. R., CHAN, L., SCHROEDER, W. A.
• Format: Article
• Language: English
• Subjects: Anemia, Sickle Cell - complications; Anemia, Sickle Cell - genetics; Fetal Hemoglobin - metabolism; Gene Expression Regulation; Haplotypes; Humans; Multigene Family; Thalassemia - genetics
• ISSN: 0077-8923; 1749-6632
• DOI: 10.1111/j.1749-6632.1989.tb24174.x

The variable levels of HbF in sickle cell anemia reflect the heterogeneous genetic mix of the beta s-gene-cluster haplotypes and coinheritance of alpha-thalassemia-2 in American SS patients. Clinical severity is less when the level of HbF reaches 20% or 1.2 g/dl or more. The coinheritance of alpha-thalassemia-2 not only increases the intracellular red cell water but modifies the HbF level in accordance with the beta-cluster haplotype. In general, the SS patient with at least one Senegalese haplotype who does not have a CAR haplotype in trans, has a significantly greater probability of maintaining HbF above 20%. This is in part related to the genetic control of the G gamma HbF locus. Such a patient is protected from arteriolar vasculopathy and subsequent major organ destruction. Much of this but perhaps not all of the better health of patients with a Senegalese haplotype can be attributed to the elevation of G gamma HbF. The coinheritance of alpha-thalassemia-2 further decreases the risk of major morbidity of the soft tissues but increases the risk of avascular necrosis of the bony skeleton. Although these heterozygous Senegal patients are healthier, eventually most, in time, will show the deleterious effect of HbS as retinopathy and avascular necrosis usually beginning after age 30 and sickle nephropathy after age 40. Because of the age-specific effect, the onset of the sickle vasculopathy is delayed by nearly 20 years in the Sen/Ben patient with increased G gamma HbF as compared to those with a CAR haplotype or the homozygous Benin. Lifetime elevation of HbF above 20% modifies the severity of disease expression and provides relative protection to the patient with sickle cell anemia.